

DISCLAIMER: These guidelines were prepared by the Department of Surgical Education, Orlando Regional Medical Center. They are intended to serve as a general statement regarding appropriate patient care practices based upon the available medical literature and clinical expertise at the time of development. They should not be considered to be accepted protocol or policy, nor are intended to replace clinical judgment or dictate care of individual patients.

ANTIPLATELET AGENT REVERSAL IN ADULTS WITH TRAUMATIC INTRACRANIAL HEMORRHAGE

SUMMARY

The use of antiplatelet agents (such as clopidogrel or aspirin) has been steadily increasing. The increasing use of antiplatelet agents raises concern for inadequate platelet aggregation in the setting of acute hemorrhage, especially intracranial hemorrhage (ICH). The purpose of this guideline is to provide recommendations for the evaluation and rapid reversal of patients on clopidogrel or aspirin who present with acute spontaneous or traumatic ICH.

RECOMMENDATIONS

- **Level 1**
 - **None**
- **Level 2**
 - **Use agent-specific (aspirin or clopidogrel) platelet function assays (PFA) to accurately assess for the presence of these agents.**
- **Level 3**
 - **In patients with TBI AND Known history of aspirin and/or clopidogrel (Plavix):**
 - **Check baseline PFA ASPIRIN and/or Plavix AND**
 - **Administer 1 unit of pheresis platelets (1 unit = 6-10 pack) IV x 1 STAT**
 - **Check an agent-specific PFA 1 hour after platelet transfusion complete**
 - **In patients with TBI AND Unknown history of aspirin or clopidogrel (Plavix):**
 - **Assess risk for administration of aspirin or clopidogrel (See Algorithm)**
 - **High Risk = treat the same as known history of aspirin and/or clopidogrel**
 - **Low Risk:**
 - **Check STAT PFA ASPIRIN & PFA PLAVIX assays**
 - **Administer 1 unit of pheresis platelets if either assay is positive**
 - **Repeat the positive PFA 1 hour after platelet transfusion complete**
 - **Minimal Risk: No further action**
 - **Consider the addition of one of the following options in patients with renal dysfunction (i.e. BUN > 20 and/or SCr >2) and active bleeding:**
 - **Desmopressin injection (dDAVP) 0.3 mcg/kg IV in 50mL NS x 1**
OR Cryoprecipitate 1 unit IV STAT

INTRODUCTION

The antiplatelet agents, aspirin, clopidogrel and ticlopidine, have a number of clinical applications including decreasing risk of atherothrombotic events such as myocardial infarction and stroke (1). Aspirin and clopidogrel are the two most widely utilized agents today, frequently in combination therapy.

EVIDENCE DEFINITIONS

- **Class I:** Prospective randomized controlled trial.
- **Class II:** Prospective clinical study or retrospective analysis of reliable data. Includes observational, cohort, prevalence, or case control studies.
- **Class III:** Retrospective study. Includes database or registry reviews, large series of case reports, expert opinion.
- **Technology assessment:** A technology study which does not lend itself to classification in the above-mentioned format. Devices are evaluated in terms of their accuracy, reliability, therapeutic potential, or cost effectiveness.

LEVEL OF RECOMMENDATION DEFINITIONS

- **Level 1:** Convincingly justifiable based on available scientific information alone. Usually based on Class I data or strong Class II evidence if randomized testing is inappropriate. Conversely, low quality or contradictory Class I data may be insufficient to support a Level I recommendation.
- **Level 2:** Reasonably justifiable based on available scientific evidence and strongly supported by expert opinion. Usually supported by Class II data or a preponderance of Class III evidence.
- **Level 3:** Supported by available data, but scientific evidence is lacking. Generally supported by Class III data. Useful for educational purposes and in guiding future clinical research.

Ticlopidine, due to a number of severe adverse events including neutropenia, agranulocytosis, and thrombotic thrombocytopenia purpura, is rarely used (2).

Aspirin exerts its effects through inhibition of cyclooxygenase-1 (COX-1) which prevents the conversion of arachidonic acid to thromboxane A₂ (3). Aspirin achieves platelet inhibition within 10 minutes following administration of a single dose (Micromedex). The result of aspirin inhibition is an irreversible inhibition of platelet aggregation which remains for 5-7 days following discontinuation of aspirin (the time required for the body to release at least 20% new circulating platelets) (1).

In contrast to aspirin, clopidogrel and ticlopidine exert their anti-platelet effects by binding to the adenosine diphosphate (ADP) receptor on platelets preventing ADP from binding and activating glycoprotein GPIIb/IIIa which is necessary to platelet activation (2,4). Clopidogrel has a slightly slower onset and typically achieves maximal platelet inhibition (40-60%) at 7 days after initiation of therapy (1). If a loading dose of 300-400mg of clopidogrel is administered, platelet inhibition occurs within 2-5 hours (4,5). The result of clopidogrel administration is also irreversible inhibition of platelet aggregation and will remain effective for the lifespan of the platelet (7-10 days) (4).

The risk of mortality following intracranial hemorrhage in a patient on warfarin therapy has been estimated to range from 16-80% (6). Several retrospective trials have been conducted to assess the impact of antiplatelet therapy on mortality associated with intracranial hemorrhage. Ohm C, et.al. found that elderly patients (age > 50 years) who were receiving antiplatelet therapy (either monotherapy or dual therapy) at the time of their traumatic brain injury (TBI) had a significantly higher mortality rate (23% versus 9% in the control group, p =0.016) (6). Similarly, Wong DK, et.al found that elderly trauma patients (mean age 65-71 years) receiving clopidogrel alone had a higher mortality compared to a matched control group (29% versus 14%) (7). For patients presenting with spontaneous intracranial hemorrhages, aspirin has been identified as an independent predictor of death (8).

LITERATURE REVIEW

Platelet Function Assays

There are a number of modalities available to evaluate platelet function. These modalities include bleeding time, platelet aggregometry, platelet works, thromboelastograph platelet mapping, impact cone and platelet analyzer, PFA-100, VASP phosphorylation state and platelet function assays (9). Each of these modalities have a number of limitations and/or are time consuming to conduct. The most recently developed test, the VerifyNow[®] rapid platelet function analyzer, was specifically designed to allow point-of-care detection of aspirin or clopidogrel resistance (9).

The PFA-100 assay uses a membrane with a standardized aperture coated with either collagen/epinephrine or collagen/adenosine diphosphate (ADP) to activate platelets and then measures the time to formation of a platelet plug for the aperture. This test is insensitive to multiple inherited clotting disorders and is also unable to detect the presence of clopidogrel therapy (9,10).

The VerifyNow[®] Aspirin assay utilizes arachidonic acid converted to thromboxane A₂ to initiate platelet activation. The results of the aspirin assay are reported as aspirin reaction units (ARU). Patients not receiving aspirin were found to have ≥ 550 ARU (sensitivity 91.4%, specificity 100%) – therefore, the presence of aspirin is determined by values < 550 ARU (10,11).

The VerifyNow[®] P2Y₁₂ assay (designated PFA Plavix at ORMC) assesses the impact of clopidogrel (Plavix[®]) or other P2Y₁₂ inhibitors administration on platelet function. This assay assesses the rate of platelet activation by ADP binding to the P2Y₁₂ receptor (the inhibition target for clopidogrel). This assay differs from the aspirin assay in that there is a clear distinction between pre-clopidogrel therapy and post-clopidogrel therapy results. Results are reported as P2Y₁₂ reaction units (PRU). A result of < 194 PRU is indicative of inhibition of platelet function by clopidogrel or other P2Y₁₂ inhibitors. A result of 194-419 PRU correlates to normal platelet aggregation (10,12,13, 30).

Interpretation of Platelet Function Assays (11, 12, 14, 15, 30)

Test	Abnormal (“Positive”)	Normal (“Negative”)
Platelet Function Assay (PFA-100®)	> 180 seconds = abnormal > 200 seconds = Aspirin effect > 300 = GP IIb/IIIa inhibitor effect	63 – 180 seconds*
Platelet Function Assay ASPIRIN (VerifyNow® Aspirin Assay)	< 550 ARU	≥ 550 ARU
Platelet Function Assay PLAVIX (VerifyNow® P2Y12 Assay)	< 194 PRU	194-419 PRU†

GP IIb/IIIa inhibitor = glycoprotein IIb/IIIa, ARU = aspirin reaction units, PRU = P2Y12 reaction units
 *Orlando Regional Medical Center (ORMC) Clinical Laboratory normal range

†Data from the package insert for the *VerifyNow® P2Y12 assay* suggests that a PFA Plavix > 194 PRU (formerly designated as < 20%) is associated with low risk of perioperative bleeding (12); a single center study in trauma patients with acute TBI targeted a PFA Plavix of ≤10% (now designated as ≥ 194 PRU) as a threshold at which platelets would not be transfused based on literature suggesting that levels of ≤10% (≥ 194 PRU) are indicative of clopidogrel resistance (13,16,17). Expert opinion suggests that PFA Plavix results of > 194 PRU may be best in patients with acute TBI.

Test Comparison (10-12, 14)

Tests	Indications	Comments
Platelet Function Assay (PFA-100®)	<ul style="list-style-type: none"> • Replaced bleeding closure time • Nonspecific test for platelet function • Use when history of anti-platelet therapy unknown • Collagen-epinephrine is tested first; if abnormal, collagen-ADP will be done automatically 	<ul style="list-style-type: none"> • Often abnormal in vWF disease • Results can be affected by low vWF, low platelets (<100K), hematocrit (<30%) & use of GP IIb/IIIa inhibitors • Insensitive to Plavix (P2Y12) effect but can screen for suspected ASA use (Epi abnormal but ADP normal) • Effective to monitor DDAVP therapy • Cost: ~\$8/test (not including tubes; supplies etc.)
Platelet Function Assay ASPIRIN (VerifyNow® Aspirin Assay)	<ul style="list-style-type: none"> • Specific test for platelet inhibition due to aspirin 	<ul style="list-style-type: none"> • Results can be affected by NSAIDs, GP IIb/IIIa inhibitors • Cost: ~\$30/test (not including tubes; supplies etc.)
Platelet Function Assay PLAVIX (VerifyNow® P2Y12 Assay)	<ul style="list-style-type: none"> • Specific test for platelet inhibition due to P2Y12 inhibitors such as clopidogrel (Plavix®) 	<ul style="list-style-type: none"> • Results can be affected by low platelets or hematocrit; and use of GP IIb/IIIa • Cost: ~\$56/test (not including tubes; supplies etc.)

NSAIDs = non-steroidal anti-inflammatory agents; ADP = adenosine diphosphate; Epi = epinephrine, DDAVP = desmopressin, GP IIb/IIIa = glycoprotein IIb/IIIa,

Reversal Strategies for Antiplatelet Agents

There are several reversal strategies available for patients on antiplatelet therapy who present with an acute intracranial hemorrhage (spontaneous or traumatic) (1). These strategies include administration of platelets, desmopressin, conjugated estrogens, and/or recombinant factor VII (1).

Ohm C et.al. conducted a retrospective review of 90 patients 50 years or older admitted with a diagnosis of ICH and known pre-admission antiplatelet administration (aspirin, clopidogrel or both). The treatment patients were matched to 89 controls with similar injuries but no pre-injury antiplatelet therapy. The most common mechanism of injury was fall and patients receiving antiplatelet therapy had significantly more co-morbid conditions (71.1% v. 34.8%, $p < 0.001$). Platelet transfusions were administered to 24 of 90 study patients and 5 of 89 control patients ($p = 0.001$). No mention was made of the quantity of platelets transfused. Platelet function assays were not routinely performed. There were no statistically significant differences in disposition of patients at discharge (6).

Downey DM, et.al. conducted a retrospective study to assess the impact of platelet transfusions in elderly TBI patients who were on chronic antiplatelet therapy prior to injury. They identified 328 patients at two different institutions who were greater than 50 years old, taking chronic antiplatelet therapy (aspirin or clopidogrel) and sustained a TBI. Of these patients, 166 received a platelet transfusion (the majority at one hospital that had a protocol to transfuse if the platelet function assay was abnormal). There was no difference in the mortality rate between the two groups (17.5% versus 16.7%, $p = 0.85$). This study was limited by its retrospective nature and did not include an assessment on the impact of time from injury to platelet transfusion on mortality (18).

Vilahur G, et.al. conducted a study in healthy volunteers to assess the efficacy of platelet transfusions in reversing the platelet inhibition caused by the combination of aspirin and clopidogrel. They established that the administration *ex vivo* of platelets could overcome the inhibition demonstrated following standard loading and maintenance doses of aspirin and clopidogrel in patients previously naïve to either agent. Their *ex vivo* model provides a guideline for the number of units of pooled platelets necessary to overcome a certain percentage of inhibition. The number of units is calculated off of the baseline platelet count and the amount of inhibition. They demonstrated normalization of platelet aggregation by the addition of as little as 20% of platelet rich plasma (PRP) to the study subjects' plasma but patients who received a 600mg clopidogrel loading dose followed by three days of 75mg per day required more donor platelets to normalize platelet aggregation (5).

% added pooled PRP*	Platelet units [†]	Platelet pools [‡]
20	5	1
40	10	2
50	12.5	2-3
60	15	3

PRP = platelet rich plasma – the percent of normal platelets added to the aspirin / clopidogrel patient's plasma to reverse the effects of anticoagulation

[†]Platelet units – increased platelet counts by 10,000 μ L

[‡]Platelet pool = 5 platelet units

Powner DJ, et.al. reviewed the options presently available to reverse antiplatelet agents. Their recommendation was a minimum of 5 units or equivalent of platelets to off-set the effects of routine aspirin or clopidogrel/ticlopidine administration. This combined with discontinuation of aspirin/clopidogrel/ticlopidine (19).

Uremic Bleeding and Platelet Dysfunction

Cryoprecipitate can be considered as a treatment option in patients with uremic bleeding. Each unit of cryoprecipitate contains variable amounts of von Willebrand factor (vWf), factor VIII, and fibrinogen. It is postulated that administration of cryoprecipitate may increase the amount of circulating functional clotting factors in the patient's plasma. It may be beneficial in acute bleeding due to its relatively quick onset of action (1 hour) but overall response may vary from patient to patient. Administration of cryoprecipitate does carry the same risks as other blood product transfusions (20).

Estrogens decrease circulating levels of antithrombin III and protein S and increase factors VII, VIII, IX, X, and prothrombin. In addition, platelet counts may also be increased (21). Livio M, et.al. administered conjugated estrogens to six patients (ages ranged from 29-61 years) with chronic renal failure and a

history of bleeding and prolonged bleeding time (≥ 20 minutes; normal range 5-7 minutes for adults). None of the patients were taking aspirin or other agents known to decrease platelet aggregation for at least 20 days. Patients were given conjugated estrogens in a dose of 0.6 mg/kg IV daily for 5 days (some patients received as many as 10 days of therapy). All patients demonstrated a decrease in bleeding time following administration of the estrogens (22).

Desmopressin (DDAVP), a vasopressin analog, is indicated for control of hemorrhage in patients with mild-to-moderate hemophilia A and von Willebrand's disease. Its primary mechanism of action is to increase circulating levels of factor VIII and von Willebrand factor (vWf) leading to secondary improvements in platelet adhesion to endothelial defects (19,20,23,24). It has also been considered for use in patients with uremia and prolonged bleeding time due to decreased expression of vWF and decreased activity of the vWF-factor VIII complex (20,21). Two advantages to DDAVP are its relatively quick onset of action (1 hour), similarity to cryoprecipitate, and lack of transfusion-related side effects. However, the effects of DDAVP do not last more than 24 hours and patients are likely to develop tachyphylaxis after a single dose of DDAVP limiting its utility for repeated dosing (20).

There have been two randomized, double-blind, placebo controlled trials using DDAVP (either 0.3 mcg/kg/dose or 0.4 mcg/kg/dose) for the treatment of uremic bleeding. Mannucci P, et.al. studied 21 patients with chronic renal failure – 12 patients were randomly assigned to either DDAVP (0.3 mcg/kg/dose) or placebo; the other nine patients were treated with DDAVP prior to nephrectomy. They demonstrated a decrease in bleeding time for all patients who received DDAVP (compared to baseline) and also one patient who received placebo. Statistical analysis was not available (23). Koehler M, et.al. administered DDAVP 0.4 mcg/kg/dose subcutaneous to 8 patients on hemodialysis with consistently prolonged bleeding times. The administration of DDAVP resulted in statistically significant decreases in bleeding time. Interestingly, the total platelet count decreased significantly following administration of DDAVP; the clinical significance of this decrease was unclear (26).

Watson AJ, et.al. conducted a small observational study on the effect of DDAVP (0.4mcg/kg/dose over 12 minutes) on bleeding time in 12 patients with chronic renal failure and a history of bleeding. All 12 patients demonstrated a significant decrease in bleeding time following administration of DDAVP (27).

Use of Desmopressin (DDAVP) in Patients on Anti-Platelet Agents

With the increasing use of anti-platelet agents such as clopidogrel and aspirin, interest has been raised for a potential role of DDAVP in the setting of acute bleeding in these patients. The use of desmopressin in patients with normal renal function who have active hemorrhage and a history of recent (within the past 7 days) of aspirin or clopidogrel (Plavix[®]) administration is mentioned in a number of review articles, however, there is a paucity of randomized controlled trials evaluating its safety and efficacy in this population (15).

Ranucci M, et.al. reported a single case on the use of DDAVP to reverse the effects of clopidogrel in a patient undergoing emergent carotid endarterectomy (CEA). They described the abnormal results of PFA-100 consistent with clopidogrel therapy. These results improved following administration of a single dose of 0.3 mcg/kg of DDAVP but did not return completely to normal. The patient underwent an uneventful CEA (28).

Gratz I, et.al. enrolled 65 patients (DDAVP n = 29, Placebo n = 30) in a randomized, double-blind, placebo-controlled trial looking at the effect of DDAVP administration on bleeding in patients on aspirin undergoing coronary artery bypass grafting (CABG). They included all patients who had taken aspirin within the 7 days prior to surgery. Patients in the DDAVP group received 0.3 mcg/kg/dose in 50mL NS infused over 30 minutes immediately after heparin reversal with protamine. Patients in the DDAVP group had significantly less chest tube and total blood loss compared to placebo ($p < 0.05$). There were no differences between groups with regard to transfusion requirements. Complications were similar between groups with 3 myocardial infarctions (MI) in the DDAVP group (1 fatal) and 1 fatal MI in the placebo group (24).

Floralda PA, et al. investigated the use of DDAVP on bleeding time in 18 patients (12 aspirin patients and 6 control patients) undergoing elective cholecystectomy. All patients underwent open cholecystectomies. Six of the aspirin patients were randomized to receive two doses of DDAVP (0.3 mcg/kg/dose over 30 minutes) at induction of anesthesia and then 6 hours later. The patients in the DDAVP group had a significantly longer preoperative bleeding time compared to placebo. DDAVP did shorten this bleeding time to a time comparable to placebo. There was no difference in postoperative bleeding time. All of the bleeding complications in this study occurred in the aspirin alone group (29).

REFERENCES

1. McMillian WD, Rogers FB. Management of prehospital antiplatelet and anticoagulant therapy in traumatic head injury: a review. *J Trauma*. 2009;66:942-50.
2. Ticlopidine. Micromedex® Healthcare Series. [Accessed 20-Oct-2010].
3. Aspirin. Micromedex® Healthcare Series. [Accessed 20-Oct-2010].
4. Clopidogrel. Micromedex® Healthcare Series. [Accessed 20-Oct-2010].
5. Vilahur G, Choi GB, Zafar MU et al. Normalization of platelet reactivity in clopidogrel-treated subjects. *J Thromb Haemost*. 2007;7:82-90.
6. Ohm C, Mina A, Howells G, et al. Effects of antiplatelet agents on outcomes for elderly patients with traumatic intracranial hemorrhage. *J Trauma*. 2005;58:518-22.
7. Wong DK, Lurie F, Wong LL. The effects of clopidogrel on elderly traumatic brain injured patients. *J Trauma*. 2008;65:1303-8.
8. Saloheimo P, Ahonen M, Juvela S, et al. Regular aspirin-use preceding the onset of primary intracerebral hemorrhage is an independent predictor for death. *Stroke*. 2006;37:129-33.
9. Michelson AD, Frelinger AL, Furman MI. Current options in platelet function testing. *Am J Cardiol*. 2006;98(suppl):4N-10N.
10. Pakala R, Waksman R. Currently available methods for platelet function analysis: advantages and disadvantages. *Cardiovasc Revasc Med*. 2011;12(5):312-22.
11. Platelet Function Assay Aspirin – Package Insert. VerifyNow® System. © 2009.
12. P2Y12 Platelet Function Assay – Package Insert. VerifyNow® System. © 2009.
13. Bansal V, Fortlage d, Lee J, et al. A new clopidogrel (Plavix®) point-of-care assay; rapid determination of antiplatelet activity in trauma patients. *J Trauma*. 2011; 70:65-70.
14. ORMC Clinical Laboratory – PFA-100 standard normal range [correct as of 05-Jan-2011].
15. Beshay JE, Morgan H, Madden C, et al. Emergency reversal of anticoagulation and antiplatelet therapies in neurosurgical patients. *J Neurosurg*. 2010; 112:307-18.
16. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. *Circulation*. 2003;107:2908-13.
17. Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention. *J Am Coll Cardiol*. 2006;47:27-33.
18. Downey DM, Monsn B, Butler KL, et al. Does platelet administration affect mortality in elderly head-injured patients taking antiplatelet medications? *Am Surg*. 2009;75(11):1100-3.
19. Powner DJ, Hartwell EA, Hoots WK, et al. Counteracting the effects of anticoagulants and antiplatelet agents during neurosurgical emergencies. *Neurosurgery*. 2005; 57:823-31.
20. Hedges SJ, Dehoney SB, Hooper JS, et al. Evidence-based treatment recommendations for uremic bleeding. *Nature Clin Prac*. 2007;3(3):138-53.
21. Voils S. Pharmacologic interventions for the management of critical bleeding. *Pharmacotherapy*. 2007;27(9 Pt 2):695-845.
22. Livio M, Mannucci PM, Viganò G, et al. Conjugated estrogens for the management of bleeding associated with renal failure. *N Engl J Med*. 1986; 315:731-5.
23. Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). *J Thromb Haemost*. 2003;1:682-9.
24. Gratz I, Koehler J, Olsen D, et al. The effect of desmopressin acetate on postoperative hemorrhage in patients receiving aspirin therapy before coronary artery bypass operations. *J Thorac Cardiovasc Surg*. 1992; 104:1417-22.
25. Mannucci PM, et al. Desamino-8-D-arginine vasopressin shortens the bleeding time in uremia. *N Engl J Med*. 1983; 308:8-12.


26. Kohler M, et.al. Subcutaneous injection of desmopressin (DDAVP): evaluation of a new, more concentrated preparation. *Haemostasis*. 1989; 1:38-44.
27. Watson AJ, Keogh JA. Effect of 1-deamino-8-D-arginine vasopressin on the prolonged bleeding time in chronic renal failure. *Nephron*. 1982; 32:49-52.
28. Ranucci M, Nano G, Pazzaglia A, et.al. Platelet mapping and desmopressing reversal of platelet inhibition during emergency carotid endarterectomy. *J Cardiothorac Vasc Anesth*. 2007;21(6):851-4.
29. Floradal PA, Sahlin S. Use of desmopressin to prevent bleeding complications in patients treated with aspirin. *Br J Surg*. 1993; 80:723-4.
30. Interpreting VerifyNow™ P2Y12 Test Results. Accumetrics website. <http://www.accumetrics.com/p2y12us/interpreting-results/>. [Accessed 30-Jul-12].

Surgical Critical Care Evidence-Based Medicine Guidelines Committee

Primary Reviewer: Kara Birrer, Pharm D
Editor: Michael L. Cheatham, MD
Last revision date: September 1, 2012

Please direct any questions or concerns to: <mailto:webmaster@surgicalcriticalcare.net>

ASSESSING RISK of PLATELET DYSFUNCTION in TRAUMATIC INTRACRANIAL HEMORRHAGE



1 unit pheresis platelets (single donor) = 6-10 random/pooled platelet packs
 PFA = Platelet Function Assay (Plavix Assay = VerifyNow P2Y12 Assay)

Interpretation:

PFA Aspirin > 550 ARU = NO aspirin-induced platelet dysfunction detected
 PFA Plavix > 194 PRU = NO clopidogrel-induced platelet dysfunction detected

Comment: at present, there is no information available regarding the ability of these PFA assays to assess for the presence of alternative medications that may also be causing platelet dysfunction (such as ginkgo, willow bark, dong quai, danshen, etc).

KNOWN RISK = Patient is on antiplatelet agents such as aspirin, clopidogrel, ticlopidine, prasugrel

***HIGH RISK**

- Sternotomy scar
- Atrial fibrillation on the monitor
- Elderly
- Sequelae of peripheral vascular disease

****LOW RISK**

- Age > 40 AND diabetes

*****MINIMAL RISK**

- Age < 40
- No known cardiovascular disease